Cost-benefit analysis of Helicobacter pylori screening

Health Policy

Volumn 70, Issue 1, 2004, Pages 85-96

  Leivo, T ^a   Salomaa, A ^a,b   Kosunen, T U ^a   Tuominen, R ^a   Farkkila M ^c   Linna, M ^d   Sintonen, H ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Vammala Health Centre   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Cost; Cost benefit; Economics; Helicobacter pylori; Screening

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ESOPHAGUS DISEASE; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MASS SCREENING; RISK BENEFIT ANALYSIS;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; FINLAND; HEALTH POLICY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MASS SCREENING; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 4143145221     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2004.02.004     Document Type: Article

References (54)

1. Forman D. Helicobacter pylori Infection: a novel risk factor in the aetiology of gastric cancer. Journal of National Cancer Institute. 83:1991;1702-1703
2. Parsonnet J. Helicobacter pylori. Infectious Diseases Clinics of North America. 12:1998;185-197
3. Kuipers E.J. Review article: exploring the link between Helicobacter pylori and gastric cancer. Alimentary Pharmacology & Therapeutics. 13(1):1999;3-11
4. The Eurogast Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993;341:1359-62.
5. Sipponen P., Varis K., Fräki O., et al. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. Scandinavian Journal of Gastroenterology. 25:1990;966-973
6. Cullen D.J., Collins B.J., Kristiansen K.J., et al. Long-term risk of peptic ulcer disease in people with Helicobacter pylori infection: a community based study. Gastroenterology. 106:1993;60. [abstract]
7. Dixon M.F., Sobala G.M., Wyatt J.I., et al. Gastric metaplasia and H. pylori-associated gastritis as predictors of the duodenal ulcer diathesis. Irish Journal of Medical Science. 161(Suppl 10):1992;11
8. Blaser M.J. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. Journal of Infectious Diseases. 161:1990;626-633
9. Graham D.Y. Can Therapy Ever Be Denied for Helicobacter pylori Infection? Gastroenterology. 113:1997;S113-S117
10. Axon A., Forman D. Helicobacter gastroduodenitis: a serious infectious disease. British Medical Journal. 314:1997;1430-1431
11. Briggs A.H., Sculpher M.J., Logan R.P., et al. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. British Medical Journal. 312:1996;1321-1325
12. Fendrick A.M., Chernew M.E., Hirth R.A., et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Archives of International Medicines. 159:1999;142-148
13. Parsonnet J., Harris R.A., Hack H.M., et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet. 348:1996;150-154
14. Davies R., Crabbe D., Roderick P., Goddard J.R., Raftery J., Patel P. A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Management Science. 5(4):2002;249-258
15. Mason J., Axon A.T., Forman D., et al. for the Leeds HELP Study Group Alimentary Pharmacology & Therapeutics. 16(3):2002;559-568
16. Roderick P., Davies R., Raftery J., Crabbe D., Pearce R., Bhandari P., et al. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technology Assessment. 7:2003;6
17. Salomaa A., Kosunen T.U., Aromaa A., et al. "Screen and treat Helicobacter pylori gastritis" project in a western community. Gut. 43(Suppl 2):1998;A112
18. Kosunen T.U., Aromaa A., Knekt P., et al. Helicobacter antibodies in 1973 and 1994 in the adult population of Vammala, Finland. Epidemiology and Infection. 119:1997;29-34
19. van Der Ende A., van Der Hulst R.W., Roorda P., et al. Evaluation of three commercial serological tests with different methodologies to assess Helicobacter pylori infection. Journal of Clinical Microbiology. 37(12):1999;4150-4152
20. Meijer B.C., Thijs J.C., Kleibeuker J.H., et al. Evaluation of eight enzyme imuunoassays for detection of immunoglobulin G against Helicobacter pylori. Journal of Clinical Microbiology. 35(1):1997;292-294
21. Xia H.H., Kalantar J.S., Wyatt J.M., et al. High sensitivity and specificity of a laboratory-based serological test, pylori DTect ELISA, for detection of Helicobacter pylori infection. Diagnostic Microbiology and Infectious. 36(2):2000;69-74
22. Wotherspoon A.C., Ortiz-Hidalgo C., Falzon M.R., et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 338:1991;1175-1176
23. Hakulinen T., Andersen A., Malker B., et al. Trends in cancer incidence in the nordic countries. A collaborative study of the five nordic cancer registries. Acta Pathologica, Microbiologica et Immunologica Scandinavica. A288(94):1986;38-41
24. Statistics Finland. OSF:Population 1999;14:93-4.
25. Forman D. The prevalence of Helicobacter pylori infection in gastric cancer. Alimentary Pharmacology & Therapeutics. 9(2):1995;71-76
26. Kokkola A., Haapiainen R., Laxen F., et al. Risk of gastric carcinoma in patients with mucosal dysplasia associated with atrophic gastritis: a follow up study. Journal of Clinical Pathology. 49:1996;979-984
27. Calam J. Clinical science of Helicobacter pylori infection: ulcers and NSAIDs. British Medical Bulletin. 54(1):1998;55-62
28. Ihamäki T., Varis K., Siurala M. Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Comparison with a computer-matched family sample. Scandinavian Journal of Gastroenterology. 14:1979;801-812
29. Sipponen P. Helicobacter pylori. A cohort phenomenon. The American Journal of Surgical Pathology. 19(1):1995;30-36
30. Dew M.J. Asymptomatic peptic ulcer disease. British Medical Journal. 285:1987;401
31. Varis K. The prevalence of ulcer disease. Vox. 10:1988;7-12. [in Finnish]
32. Katschinski B., Logan R., Davies J., et al. Prognostic factors in upper gastrointestinal bleeding. Digestive Diseases & Sciences. 39(4):1994;706-712
33. Van der Hulst R.W., Rauws E.A., Koycu B., et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology. 113:1997;1082-1086
34. Elashoff J.D., Van Deventer G., Ready T.J., et al. Long-term follow-up of duodenal ulcer patients. Journal of Clinical Gastroenterology. 5:1983;509-515
35. Danesh J., Lawrence M., Murphy M., et al. Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia. Archives of Internal Medicine. 160(8):2000;1192-1198
36. Miwa H., Hirai S., Nagahara A., et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients - a double-blind placebo-controlled study. Alimentary Pharmacology & Therapeutics. 14(3):2000;317-324
37. Moayyedi P., Zilles A., Clough M., et al. The effectiveness of screening and treating Helicobacter pylori in the management of dyspepsia. European Journal of Gastroenterology & Hepatology. 11(11):1999;1245-1250
38. Greenberg P.D., Cello J.P. Lack of effect of treatment for Helicobacter pylori on symptoms of non-ulcer dyspepsia. Archives of Internal Medicine. 159(19):1999;2283-2288
39. Talley N.J., Vakil N., Ballard E.D. II, et al. Absence of benefit of eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. New England Journal of Medicine. 341(15):1999;1106-1111
40. Gilvarry J., Buckley M.J., Beattie S., et al. Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scandinavian Journal of Gastroenterology. 32:1997;535-540
41. McColl K., Murray L., El-Omar E., et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. The New England Journal of Medicine. 339(26):1998;1869-1874
42. Peeters M. Urea breath test: a diagnostic tool in the management of Helicobacter pylori-related gastrointestinal diseases. Acta Gastroenterologica Belgica. 61(3):1998;332-335
43. Helsinki University Central Hospital. Helsinki University Hospital Price List, 1999 [in Finnish].
44. Uusimaa Health district. Uusimaa Health district health care services and prices starting from 1 January 1999 [in Finnish].
45. Lääketietokeskus Oy. Pharmaca Fennica, 1999 [price list of Finnish drugs in Finnish].
46. Suvakovic Z., Bramble M.G., Jones R., et al. Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study. Gut. 41:1997;308-313
47. Dickman P., Hakulinen T., Luostarinen T., et al. Survival of cancer patients in Finland 1955-1994. Acta Oncologica. 38(12):1999;25
48. Laine L., Lewin D.N., Naritoku W., et al. Prospective comparison of H&E, Giemsa, and Genta stains for the diagnosis of Helicobacter pylori. Gastrointestinal Endoscopy. 45(6):1997;463-467
49. Gold M, Siegel J, Russell L, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
50. Kekki M., Sipponen P., Siurala M., et al. Peptic ulcer and chronic gastritis. their relation to age and sex, and to location of ulcer and gastritis. Gastroenterolgy of Clinical Biology. 14:1990;217-223
51. Doubilet P., Begg C.B., Weinstein M.C., et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Medical Decision Making. 5:1985;157-177
52. Stone M.A., Barnett D.B., Mayberry J.F. General population screening for infection with Helicobacter pylori: a realistic option? Journal of Medical Screening. 5(3):1998;162-166
53. Moayyedi P., Feltbower R., Brown J., et al. for the Leeds HELP Study Group Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Lancet. 355:2000;1665-1669
54. Labenz J., Blum A.L., Bayerdörffer E., et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 112:1997;1442-1447